Corbus Pharmaceuticals Holdings, Inc. CRBP · Stock Open Corbus Pharmaceuticals Holdings, Inc. in new tab
Analyst price targets
Recent rating changes, newest first
Corbus Pharmaceuticals Holdings, Inc. Analysis (CRBP)
Is Corbus Pharmaceuticals Holdings, Inc. a good investment? Corbus Pharmaceuticals Holdings, Inc. (CRBP) is currently trading at 4.78 USD. Market analysts have a consensus price target of 34.03 USD. This suggests a potential upside from current levels.
Earnings Schedule: Corbus Pharmaceuticals Holdings, Inc. is expected to release its next earnings report on Nov. 11, 2026. The market consensus estimate for Forward EPS is -5.51.
Investor FAQ
Does Corbus Pharmaceuticals Holdings, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Corbus Pharmaceuticals Holdings, Inc.?
Corbus Pharmaceuticals Holdings, Inc. is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.
When is the next earnings date?
The next earnings date is projected to be Nov. 11, 2026. The company currently has a trailing EPS of -6.02.
Company Profile
Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E; and CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist for the treatment of obesity. The company was incorporated in 2009 and is headquartered in Norwood, Massachusetts.
| Split Date | Split Ratio to 1 |
|---|---|
| Feb. 14, 2023 | 1:30 |
Community Discussion